RT Journal Article
SR Electronic
T1 Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4145
OP 4150
VO 35
IS 7
A1 SHAHEEN ALANEE
A1 AARON MOORE
A1 MAX NUTT
A1 BRADLEY HOLLAND
A1 DANUTA DYNDA
A1 AHMED EL-ZAWAHRY
A1 KEVIN T. McVARY
YR 2015
UL http://ar.iiarjournals.org/content/35/7/4145.abstract
AB Aim: The purpose of the study was to provide an update ever the incidence and mortality for neuroendocrine prostate cancer (NEPC) in the United States. Patients and Methods: Using a large national database, we examined changes in age-adjusted incidence (AAIR), mortality rates (MR) and 5-year cancer-specific survival (CSS) for 378 patients diagnosed with NEPC between 1992 and 2011. Analysis was performed for all NEPC and for its two major sub-groups [small cell carcinoma (SCC) and neuroendocrine carcinoma (NEC)]. Results: AAIR of NEPC continues to rise in recent years (2004-2011:+6.8%/year, p>0.05). AAIR of SCC has been increasing significantly by 6.94%/year since 2001 (from 0.470 to 0.582/1,000,000 person years, p<0.05). Overall incidence-based mortality rates for NEPC did not change significantly since 1992 and similar trends were observed for SCC and NEC. Conclusion: The AAIR of SCC is increasing with no change in the MR of NEPC over the past 20 years.